Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + vincristine
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy combination regimen consisting of carboplatin (a platinum-based alkylating agent) and vincristine (a vinca alkaloid). This combination is primarily used in pediatric oncology, especially for the treatment of low-grade gliomas (LGGs) and other childhood cancers. The regimen has shown significant activity in both recurrent and newly diagnosed progressive LGGs, with objective response rates of 52% in recurrent disease and 62% in newly diagnosed patients.
- Other names
- C - V - C+VCarboplatin-VincristineVincristine-Carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on carboplatin + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + vincristine.